🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Check out this great review by Nicholas Chew, Cheng Han Ng, Mazen Noureddin, MD, MHSc, @KowdleyMd and Dr. Emily Truong on “Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update” in SLD: bit.ly/3EHHwz0 #LiverTwitter

Read this interesting review by Drs. Mohamed El-Kassas, Joaquin Cabezas Paula Iruzubieta, et. al on “Non-alcoholic Fatty Liver Disease: Current Global Burden” in SLD: bit.ly/3EjGaJ9 #LiverTwitter

Issue 42.4 of SEMINARS IN LIVER DISEASE, "NAFLD, Cirrhosis and HCC: from Basic Science to Clinical Outcomes," is out now! See link to issue here: bit.ly/3uiokSv. #LiverTwitter

Here you have the December 2023 issue of Seminars in Liver Disease. You can find great reviews on "Hot Topics in Basic and Clinical Hepatology: from Early Disease to HCC" 🔹Checkpoint inhibitors 🔹Steatosis 🔹Screening & ACLF @DrPMonga Ramon Bataller shorturl.at/dCFU9

Issue 44.1 of SEMINARS IN LIVER DISEASE, "Metabolic-associated Steatotic Liver Disease (MASLD): a New Name for a New Era" out now! shorturl.at/oszBQ 🔹Liver Transplantation & Cancer 🔹Novel Targets for Therapy 🔹DILI; ALD; Fibrosis Algorithms @DrPMonga Ramon Bataller

Is Ursodeoxycholic Acid (UDCA) useful for drug-induced liver disease? This great review by Fernando Bessone et al. reviews its mechanisms of action and clinical usefulness in Seminars in Liver Disease. shorturl.at/bmE69

How and when should we detect liver fibrosis in PRIMARY CARE? Read this clear article by Maja Thiele et al. on current algorithms on early detection of liver disease in high risk groups in Seminars in Liver Disease! shorturl.at/gvwWZ

What is the New Nomenclature of NASH? Is it useful? A must-read article on MASLD, MetALD and ALD nomenclature and its implications in clinical practice by Rohit Loomba et al. in Seminars in Liver Disease! shorturl.at/hpzOP

We're celebrating an increase of the impact factor for our Seminars in Liver Disease journal! Enjoy free access to the most cited articles: shorturl.at/y8q5Z shorturl.at/4Pk9E shorturl.at/yktgR #liver #liverdisease #hepatology #gastroenterology

Read Issue 44.2 "Heterogeneity in Liver Diseases: Impact on Diagnosis & Management" of SEMINARS IN LIVER DISEASE today! shorturl.at/7ItZK 🔹Spatial Biology, Research Tools 🔹Molecular Stratification 🔹MASLD, Viral Hepatitis, DILI & Hepatic Porphyria Ramon Bataller @DrPMonga

Interesting article on Emerging Roles of Spatial Transcriptomics in Liver Research by Naoto Fujiwara, et. al. #Spatialtranscriptomics #leveragingsequencingtechniques #imagingbasedtechniques, has emerged as a groundbreaking technology. shorturl.at/ItrIZ Seminars in Liver Disease

Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives by Caiyi Cherry Li, et. al. Read more about the success of immunotherapy #livercancer #immunotherapy #tumorheterogeneity shorturl.at/bwrrX

Stronger together with an overcoming resistance to immune checkpoint blockade in liver cancer with combination therapy? #hepatocellularcarcinoma #checkpointinhibitors #resistance Get the answers in the article by Wiebke Werner, et. al shorturl.at/OaIh8

Read SLD Issue 44.3 on "Steatotic Liver Disease: Pathogenesis, Biomarkers & Novel Targets for Therapy" today! shorturl.at/t7WsQ 🔹Management of Gallstones 🔹HNF4alpha in Liver Cancer 🔹Necrotic Liver Resolution & Role of Extracellular Matrix Ramon Bataller @DrPMonga

Find out more about noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease. Article by Monica A. Tincopa and Rohit Loomba #NAFLD #MASLD #MASH #noninvasivetests shorturl.at/pvy2K

Portal vein thrombosis (PVT) is one of the common complications of cirrhosis. #thrombosis #portalhypertension #anticoagulants Find out more about "Management of Portal vein Thrombosis in Cirrhosis" in the article from Babu Lal Meena and Shiv Kumar Sarin shorturl.at/tuiow

Rodents are commonly employed to model human liver conditions, although species differences can restrict their translational relevance. Read more about overcoming some of these limitations here "Mice Engrafted with Human Liver Cells" from Ype P. de Jong. tinyurl.com/39r6phzk

Read SLD Issue 44.4 on "Steatotic Liver Disease: Pathogenesis, Biomarkers and Novel Targets for Therapy" today! shorturl.at/i3AgX 🔹Management of Portal Thrombosis & ACLF 🔹Role of Complement and the Microbiome 🔹Humanized Mice Livers Ramon Bataller @DrPMonga

Drug-induced liver injury continues to be a major concern in clinical practice, thus necessitating a need for novel therapeutic approaches to alleviate its impact on hepatic function. #druginducedliverinjury #polyphenols Article by Namya Sethi, et. al shorturl.at/Dym9D

The prevalence of metabolic dysfunction, associated steatotic liver disease previously described as nonalcoholic fatty liver disease, continues to rise globally. #MASLD #NAFLD #liversteatosis #gutmicrobiome #gutliveraxis Article by Salim Maher, et. al shorturl.at/Wl48F